Literature DB >> 28209395

Highlights from the 2016 HIV diagnostics conference: The new landscape of HIV testing in laboratories, public health programs and clinical practice.

Laura G Wesolowski1, Monica M Parker2, Kevin P Delaney3, S Michele Owen4.   

Abstract

The 2016 HIV Diagnostics Conference, held in Atlanta, Georgia, was attended by public health officials, laboratorians, HIV testing program managers, surveillance coordinators and industry representatives. The conference addressed test performance data, the implementation of new testing algorithms, quality assurance, and the application of new tests in a variety of settings. With regard to the recommended Centers for Disease Control and Prevention/Association of Public Health Laboratories HIV laboratory testing algorithm, the conference featured performance data, implementation challenges such as a lack of test options for the second and third steps, as well as data needs for new tests that may be used as part of the algorithm. There are delays when nucleic acid testing is needed with the algorithm. Novel tests such as point of care nucleic acid tests are needed on the U.S. market to readily identify acute infection. Multiplex tests are being developed which allow for the simultaneous detection of multiple pathogens. CDC staff highlighted new guidance for testing in non-clinical settings. Innovative approaches to linking testing and care in some settings have led to identification of early infections, improved receipt of test results and expedited initiation of therapy. Work continues to optimize testing so that infections are accurately identified as early as possible and time to treatment is minimized to improve health outcomes and prevent transmission. Published by Elsevier B.V.

Entities:  

Keywords:  Algorithm; Conference; Diagnostics; HIV testing

Mesh:

Substances:

Year:  2017        PMID: 28209395      PMCID: PMC5440191          DOI: 10.1016/j.jcv.2017.01.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  3 in total

1.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

2.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

3.  Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population.

Authors:  Sally Fordan; Berry Bennett; Meghan Lee; Susanne Crowe
Journal:  J Clin Virol       Date:  2017-04-06       Impact factor: 3.168

  3 in total
  4 in total

Review 1.  Selecting an HIV Test: A Narrative Review for Clinicians and Researchers.

Authors:  Christopher B Hurt; Julie A E Nelson; Lisa B Hightow-Weidman; William C Miller
Journal:  Sex Transm Dis       Date:  2017-12       Impact factor: 2.830

2.  BioRad BioPlex® HIV Ag-Ab assay: Incidence of false positivity in a low-prevalence population and its effects on the current HIV testing algorithm.

Authors:  Jayme Parker; Ana Fiorella Carrasco; Jack Chen
Journal:  J Clin Virol       Date:  2019-04-06       Impact factor: 3.168

3.  Trends in testing algorithms used to diagnose HIV infection, 2011-2015, United States and 6 dependent areas.

Authors:  Anne Harwood Peruski; Xueyuan Dong; Richard M Selik
Journal:  J Clin Virol       Date:  2018-03-27       Impact factor: 3.168

4.  Performance of an Alternative Laboratory-Based HIV Diagnostic Testing Algorithm Using HIV-1 RNA Viral Load.

Authors:  Marc A Pitasi; Shilpa N Patel; Laura G Wesolowski; Silvina Masciotra; Wei Luo; S Michele Owen; Kevin P Delaney
Journal:  Sex Transm Dis       Date:  2020-05       Impact factor: 3.868

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.